NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.62 -0.02 (-3.13 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$0.64
Today's Range$0.60 - $0.66
52-Week Range$0.60 - $2.38
Volume523,800 shs
Average Volume390,824 shs
Market Capitalization$45.46 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
Previous Symbol
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio10.81
Quick Ratio10.22

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales88.09
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book1.09

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-27,360,000.00
Net MarginsN/A
Return on Equity-91.16%
Return on Assets-76.86%

Miscellaneous

Employees36
Outstanding Shares71,040,000
Market Cap$45.46 million
OptionableNot Optionable

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced its quarterly earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.08. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

3 analysts have issued 1-year price targets for Catabasis Pharmaceuticals' stock. Their predictions range from $1.50 to $7.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $3.8333 in the next year. This suggests a possible upside of 518.3% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.

What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

Media stories about CATB stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)
  • Dr. Angelika Fretzen, Sr. VP of Product Devel.

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.05%), Oppenheimer & Co. Inc. (0.72%), Renaissance Technologies LLC (0.64%) and BlackRock Inc. (0.24%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Which major investors are selling Catabasis Pharmaceuticals stock?

CATB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Stonepine Capital Management LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals.

Which major investors are buying Catabasis Pharmaceuticals stock?

CATB stock was bought by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc. and BlackRock Inc.. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $0.62.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $45.46 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is http://www.catabasis.com.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Featured Article: Reverse Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel